


HPW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. RLL-291US	
In Re Application Of: DAS et al.						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/573,275	I.A. 9/25/2003	Unknown	26815	Unknown	9226	
Title: 3,4-DI-SUBSTITUTED-3-O-SUBSTITUTED ERYTHRONOLIDE A DERIVATIVES						
<p>Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</p> <p>37 CFR 1.97(b)</p> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p style="text-align: center;">37 CFR 1.97(c)</p> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p style="padding-left: 40px;"><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center;">OR</p> <p style="padding-left: 40px;"><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p>						



TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-291US

In Re Application of: DAS et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/573,275	I.A. 9/25/2003	Unknown	26815	Unknown	9226

Title: 3'-N-SUBSTITUTED-3-O-SUBSTITUTED ERYTHRONOLIDE A DERIVATIVES



Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

April 11, 2007

(Date)

Signature of Person Mailing Correspondence

Christine Kenedy-Renner

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by deposit account.**

Signature

William D. Hare, Esq.
Reg. No. 44,739

CUSTOMER NO. 26815

Dated: April 11, 2007

CC:

INFORMATION DISCLOSURE CITATION



Docket No.: RLL-291US

Serial No.: 10/573,275

Applicants: DAS et al.

Filed: 3/23/2006

Group:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/E.P./	A1	US 3,923,784	12/2/1975	Kierstead et al.	260	210E	
/E.P./	A2	US 4,331,803	5/25/1982	Watanabe et al.	536	7.2	
/E.P./	A3	US 4,742,049	5/3/1988	Baker et al.	514	29	
/E.P./	A4	US 5,444,051	8/22/1995	Agouridas et al.	514	29	
/E.P./	A5	US 6,034,069	3/7/2000	Or et al.	514	29	
/E.P./	A6	US 6,077,943	6/20/2000	Omura et al.	536	7.2	
/E.P./	A7	US 6,084,079	7/4/2000	Keyes et al.	536	7.2	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
/E.P./	B1	EP 0 215 355	3/25/1987	EPO	C07H	17/08		
/E.P./	B2	EP 0 272 110	6/22/1988	EPO	C07H	17/08		
/E.P./	B3	EP 0 487 411	5/27/1992	EPO	C07H	17/08		
/E.P./	B4	EP 0 596 802	5/11/1994	EPO	C07H	17/00		
/E.P./	B5	EP 0 619 320	10/12/1994	EPO	C07H	17/08		
/E.P./	B6	EP 0 945 459	9/29/1999	EPO	C07H	17/08		
/E.P./	B7	EP 1 044 985	10/18/2000	EPO	C07H	17/08		
/E.P./	B8	WO 92/09614	6/11/1992	PCT	C07H	17/00		
/E.P./	B9	WO 97/10251	3/20/1997	PCT	C07H	17/08		
/E.P./	B10	WO 97/17356	5/15/1997	PCT	C07H	17/08		

EXAMINER

/Elli Peselev/

DATE CONSIDERED

10/22/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-291US	Serial No.: 10/573,275
	Applicants: DAS et al.	
	Filed: 3/23/2006	Group:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/E.P./	C1	Yassin and Dever, "Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections", <i>Expert Opinion on Investigational Drugs</i> , <u>10</u> (2):353-367 (2001)
/E.P./	C2	Itoh et al, "Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog", <i>American Journal of Physiology - Gastrointestinal and Liver Physiology</i> , <u>247</u> (6):G688-G694 (1984)
/E.P./	C3	Morimoto et al, "Chemical Modification of Erythromycins. II. Synthesis and Antibacterial Activity of O-alkyl Derivatives of Erythromycin A", <i>The Journal of Antibiotics</i> , <u>43</u> (3):286-294 (1990)
/E.P./	C4	Morimoto et al, "Chemical Modification of Erythromycins. I. Synthesis and Antibacterial Activity of 6-O-methylethromycins A", <i>The Journal of Antibiotics</i> , <u>37</u> (2): 187-189 (1984)
/E.P./	C5	Omura et al, "Macrolides with Gastrointestinal Motor Stimulating Activity", <i>Journal of Medicinal Chemistry</i> , <u>30</u> (11):1941-1943 (1987)
/E.P./	C6	LeMahieu et al, "Glycoside Cleavage Reactions on Erythromycin A. Preparation of Erythronolide A", <i>Journal of Medicinal Chemistry</i> , <u>17</u> (9):953-956 (1974)
/E.P./	C7	Tanikawa et al, "Synthesis and Antibacterial Activity of Acylides (3-O-Acyl-erythromycin Derivatives): A Novel Class of Macrolide Antibiotics", <i>Journal of Medicinal Chemistry</i> , <u>44</u> (24):4027-4030 (2001)
/E.P./	C8	Tanikawa et al, "Synthesis and Antibacterial Activity of a Novel Series of Acylides: 3-O-(3-Pyridyl)acetylerythromycin A Derivatives", <i>Journal of Medicinal Chemistry</i> , <u>46</u> (13):2706-2715 (2003)
/E.P./	C9	LeMahieu et al, "Aromatic Esters of 5-O-Desosaminylerythronolide A Oxime", <i>Journal of Medicinal Chemistry</i> , <u>18</u> (8):849-851 (1975)
/E.P./	C10	Pestka and LeMahieu, "Effect of Erythromycin Analogues on Binding of [¹⁴ C]Erythromycin to <i>Escherichia coli</i> Ribosomes" <i>Antimicrobial Agents and Chemotherapy</i> , <u>6</u> (4):479-488 (1974)

EXAMINER	/Elli Peselev/	DATE CONSIDERED	10/22/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			